Picture of Evofem Biosciences logo

EVFM — Evofem Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Evofem Biosciences Inc expected to post a loss of 23  cents a share - Earnings Preview

* Evofem Biosciences Inc  EVFM.OQ   EVFM.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 3. 
    * The San Diego California-based  company is expected to
report  a
1,898.0% increase in revenue to $3.357 million from $168
thousand a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Evofem Biosciences
Inc is
for a loss of 23 cents per share. For the same quarter last
year, the company reported a loss of 50 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evofem
Biosciences Inc is $2​, about 75.1% above​ its last closing
price of $0.50. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.30       -0.29      -0.48     Missed  -62.7
 Jun. 30 2021  -0.37       -0.37      -0.27     Beat    26.5
 Mar. 31 2021  -0.49       -0.49      -0.56     Missed  -14.9​
 Dec. 31 2020  -0.40       -0.36      -0.50     Missed  -37.9
 ​​Sep.        -0.44       -0.44      -0.37     Beat    15.9
 30 2020                                                
 Jun. 30 2020  -0.37       -0.37      -0.91     Missed  -143.8
                                                        ​
 Mar. 31 2020  -0.33       -0.32      -0.40     Missed  -25
 Dec. 31 2019  -0.28       -0.29      -0.27     Beat    6.3
 This summary was machine generated March 1 at 22:49 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Evofem Biosciences

See all news